The aim of this statistical note is to describe the results of the randomized controlled clinical trial TARGET, which compared the effect of tirofiban (new treatment) and abciximab (standard treatment) in patients who were expected to undergo coronary stenting. Primary aim of TARGET was to evaluate the non-inferiority of tirofiban with respect to abciximab, but it concluded in favor of superiority of the standard treatment. The authors of this study point out that a deep consideration regarding a priori available evidence could have avoided to expose 2398 patients randomized to tirofiban to the risk of death or non-fatal myocardial infarction.
Note statistiche. A quali rischi espone i propri pazienti il cardiologo che accetta di partecipare ad una sperimentazione clinica senza un'approfondita riflessione sulle evidenze disponibili a priori? / E. Marubini, P. Rebora, G. Reina. - In: GIORNALE ITALIANO DI CARDIOLOGIA. - ISSN 1827-6806. - 7:5(2006 May), pp. 344-347.
Note statistiche. A quali rischi espone i propri pazienti il cardiologo che accetta di partecipare ad una sperimentazione clinica senza un'approfondita riflessione sulle evidenze disponibili a priori?
E. MarubiniPrimo
;P. ReboraSecondo
;G. ReinaUltimo
2006
Abstract
The aim of this statistical note is to describe the results of the randomized controlled clinical trial TARGET, which compared the effect of tirofiban (new treatment) and abciximab (standard treatment) in patients who were expected to undergo coronary stenting. Primary aim of TARGET was to evaluate the non-inferiority of tirofiban with respect to abciximab, but it concluded in favor of superiority of the standard treatment. The authors of this study point out that a deep consideration regarding a priori available evidence could have avoided to expose 2398 patients randomized to tirofiban to the risk of death or non-fatal myocardial infarction.Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.